Industry Updates
Cure SMA Shares Research Insights with Scientists and Clinicians at Fall 2026 Conferences
At research conferences this fall, staff from Cure SMA’s Research Department presented results from two studies made possible by the SMA Industry Collaboration (SMA‑IC). Through […]
An Update for Our Community on Recent Zolgensma Safety Reports
At Cure SMA, the safety and well-being of everyone impacted by spinal muscular atrophy (SMA) guide everything we do. We are aware of recent reports […]
Cure SMA Launches Their “This Gen Next 10” Campaign
Today, Cure SMA is proud to launch our year-end campaign: This Gen, Next 10. It’s a chance to look at where this community started, how […]
Biogen Shares Update on the Salanersen Development Program
(opens in new tab) From newly opened Phase 3 studies enrolling infants through adults to the first participants already dosed in the U.S. and Japan, […]
Scholar Rock Receives Approval for ISEMBYLD™ for the Treatment of SMA
Scholar Rock today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for ISEMBYLD™ (apitegromab-mstn) to treat spinal muscular atrophy […]
Genentech Shares Highlights from an Unforgettable Week at the Annual SMA Conference
(opens in new tab) From a lively “Evryday Café” exhibit hall experience to an advocacy reception featuring conversations on policy and access, Genentech recaps a […]
Novartis Highlights Accessible Travel Partnership in Summer Community Update
From their time at the Cure SMA Annual Conference, to their SMAshing My Limits partnership with Becoming rentABLE, opening up accessible beach houses, treehouses, and […]
Biogen Shares Conference Highlights and New High Dose SPINRAZA Resources
From the High Dose SPINRAZA symposium to a family-friendly poster session, Biogen recaps their experience at this year’s Annual SMA Conference and highlights new tools […]
FDA Grants Breakthrough Therapy Designation to Biogen’s Salanersen for Spinal Muscular Atrophy
Biogen recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to salanersen, an investigational therapy being studied for the […]
NMD Pharma Releases Community Letter Regarding Phase 2 SYNAPSE-SMA Clinical Trial
NMD Pharma recently shared exciting news with the SMA community: the last participant has completed their part in the SYNAPSE-SMA Phase 2 clinical trial, testing […]